Upgrade to SI Premium - Free Trial

UPDATE: Lexicon Pharma (LXRX) Reports Prelim. Update for Zynquista (Sotagliflozin) Type 2 Diabetes Phase 3 Program; Confirms Sanofi (SNY) to Terminate Collaboration

July 29, 2019 5:45 AM
(Updated - July 29, 2019 5:47 AM EDT)Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), received preliminary topline results from Sanofi for three ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles